We aimed to compare the efficacy of genotypic resistance-guided tailored therapy vs empirical therapy for eradication of Helicobacter pylori (H. pylori) infection in randomized controlled trials.
Name: triple therapy
Description: esomeprazole 40 mg, amoxicillin 1 g, clarithromycin 500 mg twice a day for 10 daysType: Combination ProductEmpirical group Genotypic resistance-guided tailored group
Name: quadruple therapy
Description: esomeprazole 40 mg and bismuth 300mg twice daily, tetracycline 500 mg four times daily, metronidazole 500mg three times daily for 10 daysType: Combination ProductGenotypic resistance-guided tailored group
Name: dual-priming oligonucleotide-based multiplex (DPO)-PCR test
Description: Resistance of clarithromycin 23S rRNA point mutationType: Diagnostic TestGenotypic resistance-guided tailored group
Description: Eradication rate of H. pylori infection
Measure: Eradication rate Time: 13C-UBT at least 4 weeks after completion of treatmentAllocation: Randomized
Parallel Assignment
There are 2 SNPs
This is a method to confirm the mutation of A2142G and A2143G by PCR, which are known to be highly related to the resistance of clarithromycin 23S rRNA point mutation. --- A2142G ---
This is a method to confirm the mutation of A2142G and A2143G by PCR, which are known to be highly related to the resistance of clarithromycin 23S rRNA point mutation. --- A2142G --- --- A2143G ---